Literature DB >> 28492063

Vaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A Virus.

Pei-Feng Liu1, Yanhan Wang1, Yu-Tsueng Liu2,3, Chun-Ming Huang1,3.   

Abstract

There is a need for a fast and simple method for vaccine production to keep up with the pace of a rapidly spreading virus in the early phases of the influenza pandemic. The use of whole viruses produced in chicken eggs or recombinant antigens purified from various expression systems has presented considerable challenges, especially with lengthy processing times. Here, we use the killed but metabolically active (KBMA) Escherichia coli (E. coli) to harbor the hemagglutinin (HA) of swine origin influenza A (H1N1) virus (S-OIV) San Diego/01/09 (SD/H1N1-S-OIV). Intranasal vaccination of mice with KBMA E. coli SD/H1N1-S-OIV HA without adding exogenous adjuvants provoked detectable neutralizing antibodies against the virus-induced hemagglutination within three weeks. Boosting vaccination enhanced the titers of neutralizing antibodies, which can decrease viral infectivity in Madin-Darby canine kidney (MDCK) cells. The antibodies were found to specifically neutralize the SD/H1N1-S-OIV-, but not seasonal influenza viruses (H1N1 and H3N2), -induced hemagglutination. The use of KBMA E. coli as an egg-free system to produce anti-influenza vaccines makes unnecessary the rigorous purification of an antigen prior to immunization, providing an alternative modality to combat influenza virus in future outbreaks.

Entities:  

Keywords:  H1N1 swine origin influenza A virus; Hemagglutinin; Intranasal vaccine; KBMA; microbe based-vaccine

Year:  2017        PMID: 28492063      PMCID: PMC5421401     

Source DB:  PubMed          Journal:  J Nat Sci        ISSN: 2377-2700


  48 in total

1.  West Nile virus: reducing the risk.

Authors:  Linda Bren
Journal:  FDA Consum       Date:  2003 Jan-Feb

Review 2.  Mucosal vaccines: novel advances in technology and delivery.

Authors:  Yoshikazu Yuki; Hiroshi Kiyono
Journal:  Expert Rev Vaccines       Date:  2009-08       Impact factor: 5.217

3.  Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris.

Authors:  Pei-Feng Liu; Teruaki Nakatsuji; Wenhong Zhu; Richard L Gallo; Chun-Ming Huang
Journal:  Vaccine       Date:  2011-02-26       Impact factor: 3.641

4.  Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

Authors:  Isaac Sipo; Mathias Knauf; Henry Fechner; Wolfgang Poller; Oliver Planz; Reinhard Kurth; Stephen Norley
Journal:  Vaccine       Date:  2010-12-30       Impact factor: 3.641

5.  Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector.

Authors:  Alexander J Lankowski; Elizabeth L Hohmann
Journal:  J Infect Dis       Date:  2007-03-05       Impact factor: 5.226

Review 6.  Commensals upon us.

Authors:  M N Alekshun; S B Levy
Journal:  Biochem Pharmacol       Date:  2006-02-07       Impact factor: 5.858

7.  NEW technologies for meeting the global demand for pandemic influenza vaccines.

Authors:  David S Fedson
Journal:  Biologicals       Date:  2008-08-19       Impact factor: 1.856

8.  Synthesis of biologically active influenza virus hemagglutinin in insect larvae.

Authors:  K Kuroda; A Gröner; K Frese; D Drenckhahn; C Hauser; R Rott; W Doerfler; H D Klenk
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

9.  Expression of the influenza virus haemagglutinin in insect cells by a baculovirus vector.

Authors:  K Kuroda; C Hauser; R Rott; H D Klenk; W Doerfler
Journal:  EMBO J       Date:  1986-06       Impact factor: 11.598

10.  Antibodies to a full-length VAR2CSA immunogen are broadly strain-transcendent but do not cross-inhibit different placental-type parasite isolates.

Authors:  Marion Avril; Marianne J Hathaway; Anand Srivastava; Sébastien Dechavanne; Mirja Hommel; James G Beeson; Joseph D Smith; Benoît Gamain
Journal:  PLoS One       Date:  2011-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.